Add-On Sitagliptin Cuts Risk of Insulin Initiation in T2DM

This article originally appeared here.
Share this content:
Add-On Sitagliptin Cuts Risk of Insulin Initiation in T2DM
Add-On Sitagliptin Cuts Risk of Insulin Initiation in T2DM

FRIDAY, Oct. 2, 2015 (HealthDay News) -- For patients with type 2 diabetes mellitus (T2DM) treated with metformin, add-on sitagliptin is associated with a lower risk of insulin initiation than add-on sulphonylurea, according to a study published in the October issue of Diabetes, Obesity and Metabolism.

Silvio E. Inzucchi, M.D., from the Yale University School of Medicine in New Haven, Conn., and colleagues conducted a retrospective cohort study to examine time to insulin initiation among patients with T2DM treated with sitagliptin versus sulphonylurea as an add-on to metformin. Participants were aged 18 years and older with continuous medical records and an initial prescription of sitagliptin or sulphonylurea with metformin for 90 days or more during 2006 to 2013. A total of 3,864 propensity-score-matched pairs were analyzed.

The researchers found that the risk of insulin initiation was lower for sitagliptin users versus sulphonylurea users over six years (26.6 versus 34.1 percent). After adjustment for baseline characteristics, the findings persisted (hazard ratio, 0.76; 95 percent confidence interval, 0.65 to 0.9). Compared with sulphonylurea users, sitagliptin users were less likely to initiate insulin in conditional logistic regression analyses.

"In this real-world matched cohort study, patients with T2DM treated with sitagliptin had a significantly lower risk of insulin initiation compared with patients treated with sulphonylurea, both as add-on to metformin," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Merck, the manufacturer of sitagliptin.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ancient Gene Protects Elephants From Cancer

Ancient Gene Protects Elephants From Cancer

The LIF6 gene destroys cells with damaged DNA

Reasons for Undergoing Cosmetic Procedures Explored

Reasons for Undergoing Cosmetic Procedures Explored

Psychological and emotional motivations more likely in patients wanting acne scar tx, tattoo removal

DNR Orders Linked to Increased Mortality in Older Adults

DNR Orders Linked to Increased Mortality in Older ...

Early versus late DNR tied to shorter median length of stay in hospitalized adults aged 65 years and older

is free, fast, and customized just for you!




Already a member?

Sign In Now »